Astellas Pharma Inc. (ALPMY)
PNK: ALPMY
· Real-Time Price · USD
9.86
-0.05 (-0.50%)
At close: May 01, 2025, 3:59 PM
-0.50% (1D)
| Bid | 9.84 |
| Market Cap | 17.65B |
| Revenue (ttm) | 1,701.8B |
| Net Income (ttm) | 17.38B |
| EPS (ttm) | 0.2 |
| PE Ratio (ttm) | 49.3 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 9.92 |
| Volume | 1,769 |
| Avg. Volume (20D) | 207,226 |
| Open | 9.96 |
| Previous Close | 9.91 |
| Day's Range | 9.63 - 9.96 |
| 52-Week Range | 8.37 - 13.14 |
| Beta | 0.17 |
About ALPMY
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a ...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Dec 29, 2009
Employees 14,754
Stock Exchange PNK
Ticker Symbol ALPMY
Website https://www.astellas.com
2 months ago · https://www.marketscreener.com
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate CancerPfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (...
